… Engineering immune cells to target cancer is a rapidly advancing technology. The first
commercial products, chimeric-antigen receptor (CAR) T cells, are now approved for hematologic …

… parameters that affect the chimeric antigen receptor T cells (CAR-T’s) activation, … chimeric
antigen receptor–modified T cells in patients with EGFR-positive advanced biliary tract cancers…

… Cellular immunotherapy plays an indispensable role in cancer treatment. Chimeric antigen
receptor (CAR)–engineered T cells therapy, especially for the treatment of hematological …

… T-cell escape of tumor cells lacking T-cell antigen or APPM expression, we generated tumor
cells susceptible to killing by TCR-engineered T cells. … encoding HLA or antigen required for …

… to inactivate NK cells [23]. Engineering NK cells to express a chimeric antigen receptor (CAR)
may … Although several approaches including CAR T cells, checkpoint inhibitors, antibodies, …

… immunoreceptor with Ig and ITIM domains (TIGIT)-CD28 switch receptor-modified T cells
have demonstrated superior antitumor function in a melanoma xenograft model [115]. Similar …

… growth factor receptor 2 chimeric antigen receptor T cells (HER2.CAR-T) and CD19.CAR-…
Human epidermal growth factor receptor 2 chimeric antigen receptor T cells (HER2.CAR-…

… A schematic overview of the immunosuppressive tumour microenvironment for chimeric
antigen receptor (CAR) T cells. CAR-T cells efficacy is hindered in the overall …

… utilizing chimeric antigen receptor T cells (CAR-T) targeting cancer-specific antigens would
be a … The immunotherapeutic regimen of CAR-T cell therapy has shown potential in the …

… Chimeric antigen receptor (CAR) T cell therapy mediates unprecedented benefit in certain
leukemias and lymphomas, but has yet to achieve similar success in combating solid tumors. …